An ABO-incompatible kidney transplant is a surgical procedure in which a patient receives a kidney from a living donor whose blood group is not conventionally compatible with the recipient's blood type. This approach can expand the living donor pool for patients with end-stage kidney disease who do not have a suitable ABO-compatible donor.

In conventional kidney transplantation, donor and recipient blood groups are assessed to minimise the risk of immune rejection. In ABO-incompatible transplantation, specialised treatment is used to reduce antibodies directed against the donor's blood group before surgery.

Indian transplant centres offer this procedure to carefully selected patients following comprehensive medical and immunological evaluation. The Indian Society of Organ Transplantation recognises ABO-incompatible transplantation as a higher-immunological-risk procedure requiring appropriate specialist protocols.

The ABO-incompatible kidney transplant procedure involves several stages, beginning with donor evaluation and immunological testing. The transplant team assesses blood group compatibility, anti-A or anti-B antibody levels, HLA compatibility, crossmatch results, kidney function, and the overall health of both donor and recipient.

The main stages include:

1. Pre-transplant evaluation: The transplant team reviews medical history, kidney function, infection screening, donor suitability, and antibody levels.

2. Desensitization therapy: Patients may receive plasma exchange or immunoadsorption to reduce blood group antibodies. Rituximab and other immunosuppressive medicines may be used according to the centre's protocol.

3. Antibody monitoring: Blood tests are performed to assess antibody levels and determine whether transplantation can proceed safely under the centre's criteria.

4. Kidney transplant surgery: The donor kidney is surgically implanted when the transplant team determines that the immunological and medical conditions are acceptable.

5. Post-transplant monitoring: The recipient undergoes regular kidney-function tests, antibody monitoring, and assessment for rejection and infection.

Indian working-group recommendations describe antibody-titre assessment and desensitization protocols as important components of ABO-incompatible transplantation. The exact protocol and antibody threshold differ according to the testing method and transplant centre.

The success of ABO-incompatible kidney transplantation depends on donor suitability, antibody levels, immunological risk, transplant-centre experience, and post-operative care. Published Indian studies demonstrate that successful transplantation is possible, although outcomes vary between hospitals and patient groups.

A multicentre Indian study involving 1,759 living-donor ABO-incompatible kidney transplants performed at 25 centres between 2011 and 2022 reported graft loss in 7.73% and biopsy-proven acute rejection in 12.96% of patients over a median follow-up of approximately 36 months. The researchers reported overall outcomes comparable with ABO-compatible transplantation in an unmatched analysis.

A separate single-centre Indian study published in 2024, covering 195 patients with available one-year follow-up data, reported:

These figures come from specific retrospective studies and should not be presented as a guaranteed or universal 2026 success rate. Patient survival and graft survival are different measures, and results depend on follow-up duration and patient characteristics. Individual transplant candidates should request the treating hospital's audited outcome data and discuss their personal risks with the transplant team.

ABO-incompatible kidney transplantation requires specialised immunosuppressive treatment and close monitoring because the recipient's immune system may recognise the donor kidney as foreign. Compared with conventional compatible transplantation, certain patients may face increased risks of antibody-mediated rejection and infection.

Potential complications include antibody-mediated rejection, delayed graft function, urinary tract infections, sepsis, bleeding, medication-related side effects, and surgical complications. The intensity of desensitization and immunosuppression is determined by the patient's immunological risk and medical condition.

Recovery usually involves hospitalisation after surgery, frequent laboratory testing, and ongoing transplant-clinic visits. The patient must take prescribed immunosuppressive medicines consistently and undergo regular monitoring of creatinine, kidney function, antibody levels, and signs of infection or rejection.

A 2024 Indian single-centre study identified urinary tract infections as a frequent complication and reported antibody-mediated rejection in 15% of the studied patients during the first year. These findings emphasise the importance of infection prevention and continued specialist follow-up.

Recovery timelines vary according to surgical progress, kidney function, and complications. International patients should coordinate post-transplant follow-up, accommodation, medication supply, and travel clearance with their treating hospital before returning home.

The cost of an ABO-incompatible kidney transplant in India depends on the hospital, donor and recipient evaluation, desensitization protocol, number of plasma exchange or immunoadsorption sessions, medicines, surgical requirements, hospital stay, and management of complications.

ABO-incompatible transplantation may cost more than a conventional compatible kidney transplant because it can require additional antibody-removal procedures, specialised laboratory testing, and immunosuppressive treatment. There is no single fixed price applicable to every Indian hospital or international patient.

Patients considering treatment in India should request an itemised estimate covering donor assessment, recipient investigations, desensitization, transplant surgery, intensive care if required, hospitalisation, medicines, and post-operative monitoring.

Before selecting a hospital, international patients should confirm:

• Experience with ABO-incompatible living-donor kidney transplantation.

• Availability of transplant nephrologists, transplant surgeons, and specialised immunology laboratories.

• Access to plasma exchange or immunoadsorption and antibody monitoring.

• Written treatment plans, package inclusions, exclusions, and follow-up arrangements.

• Support for medical visas, accommodation, interpreters, and international patient coordination.

Kidney transplantation in India is regulated under applicable organ transplantation laws. Patients and donors must undergo the required legal and medical approvals before transplantation. A transplant centre should explain the applicable donor eligibility, authorisation, and documentation process.

ABO-incompatible kidney transplantation may provide an additional option for selected patients who lack an ABO-compatible living donor. The decision should be based on individual medical evaluation, transparent discussion of risks and alternatives, and consultation with an experienced transplant team.